Patent ID: 8778896

Claim:
A levoisovalerylspiramycin, being the one of levoisovalerylspiramycin I, II or III compound, wherein, the chemical structural formula of levoisovalerylspiramycin I compound is shown as formula (I), on the condition of chloroform as solvent, temperature 25° C., and concentration 0.02 g/ml, the measured specific optical rotation [α] D is −49°˜−62°; and the melting point is 116˜122° C.; the chemical structural formula of levoisovalerylspiramycin II compound is shown as formula (II), on the condition of chloroform as solvent, temperature 25° C., and concentration 0.02 g/ml, the measured specific optical rotation [α] D is −55°˜−61°; and the melting point is 120° C.˜128° C.; the chemical structural formula of levoisovalerylspiramycin III compound is shown as formula (III), on the condition that chloroform as solvent, temperature 25° C., and concentration 0.02 g/ml, the measured specific optical rotation [α] D is −49°˜−51°; and the melting point is 116° C.˜118° C.; wherein: levoisovalerylspiramycin I compound is a crystalline compound, X-ray powder diffraction of which measured by Cu-Ka ray has characteristic peaks at 2θ=7.6°, 8.0°, 10.0°, 11.4°, 16.4°, 17.0°, 17.5°, 17.9°, 19.5°, 22.7°, 23.7° and 24.4°; levoisovalerylspiramycin II compound is a crystalline compound, X-ray powder diffraction of which measured by Cu-Ka ray has characteristic peaks at 2θ=10.0°, 11.6°, 16.4°, 17.3°, 19.1°, 21.2°, 22.1°, 22.7°, 26.4°, 26.9°, 27.5° and 31.5°; levoisovalerylspiramycin III compound is a crystalline compound, X-ray powder diffraction of which measured by Cu-Ka ray has characteristic peaks at 2θ=8.0°, 10.0°, 11.2°, 11.7°, 16.4°, 19.1°, 19.6°, 20.0°, 21.4°, 22.9°, 23.6° and 29.4°.